vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Perion Network Ltd. (PERI). Click either name above to swap in a different company.
Perion Network Ltd. is the larger business by last-quarter revenue ($368.7M vs $196.9M, roughly 1.9× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $-2.9M). Over the past eight quarters, Perion Network Ltd.'s revenue compounded faster (16.4% CAGR vs 8.5%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Perion Network Ltd. is a publicly traded advertising technology company that provides digital advertising technology solutions to advertisers, agencies, retailers, and publishers. Its core offerings are delivered through Perion One, a unified omnichannel advertising platform designed to support campaign planning, activation, optimisation, and measurement across channels and verticals including connected television (CTV), digital out-of-home (DOOH), display, video advertising, as well as retai...
PCRX vs PERI — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.9M | $368.7M |
| Net Profit | — | $7.7M |
| Gross Margin | 79.5% | — |
| Operating Margin | 1.2% | 2.0% |
| Net Margin | — | 2.1% |
| Revenue YoY | 5.1% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.05 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.9M | — | ||
| Q3 25 | $179.5M | $368.7M | ||
| Q2 25 | $181.1M | $266.5M | ||
| Q1 25 | $168.9M | $157.8M | ||
| Q4 24 | $187.3M | — | ||
| Q3 24 | $168.6M | $508.9M | ||
| Q2 24 | $178.0M | $323.6M | ||
| Q1 24 | $167.1M | $145.2M |
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $7.7M | ||
| Q2 25 | $-4.8M | $5.6M | ||
| Q1 25 | $4.8M | $11.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | $78.0M | ||
| Q2 24 | $18.9M | $45.2M | ||
| Q1 24 | $9.0M | $23.8M |
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — | ||
| Q1 24 | 71.6% | — |
| Q4 25 | 1.2% | — | ||
| Q3 25 | 3.5% | 2.0% | ||
| Q2 25 | 4.7% | -1.7% | ||
| Q1 25 | 1.2% | 5.4% | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | -82.8% | 15.1% | ||
| Q2 24 | 15.9% | 13.7% | ||
| Q1 24 | 7.9% | 16.9% |
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | 2.1% | ||
| Q2 25 | -2.7% | 2.1% | ||
| Q1 25 | 2.8% | 7.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | 15.3% | ||
| Q2 24 | 10.6% | 14.0% | ||
| Q1 24 | 5.4% | 16.4% |
| Q4 25 | $0.05 | — | ||
| Q3 25 | $0.12 | — | ||
| Q2 25 | $-0.11 | — | ||
| Q1 25 | $0.10 | — | ||
| Q4 24 | $0.38 | — | ||
| Q3 24 | $-3.11 | — | ||
| Q2 24 | $0.39 | — | ||
| Q1 24 | $0.19 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $238.4M | $156.2M |
| Total DebtLower is stronger | $372.2M | — |
| Stockholders' EquityBook value | $693.1M | $722.9M |
| Total Assets | $1.3B | $915.5M |
| Debt / EquityLower = less leverage | 0.54× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $238.4M | — | ||
| Q3 25 | $246.3M | $156.2M | ||
| Q2 25 | $445.9M | $156.2M | ||
| Q1 25 | $493.6M | $156.2M | ||
| Q4 24 | $484.6M | — | ||
| Q3 24 | $453.8M | $187.6M | ||
| Q2 24 | $404.2M | $187.6M | ||
| Q1 24 | $325.9M | $187.6M |
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $693.1M | — | ||
| Q3 25 | $727.2M | $722.9M | ||
| Q2 25 | $757.8M | $722.9M | ||
| Q1 25 | $798.5M | $722.9M | ||
| Q4 24 | $778.3M | — | ||
| Q3 24 | $749.6M | $718.1M | ||
| Q2 24 | $879.3M | $718.1M | ||
| Q1 24 | $892.2M | $718.1M |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | $915.5M | ||
| Q2 25 | $1.5B | $915.5M | ||
| Q1 25 | $1.6B | $915.5M | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | $1.1B | ||
| Q2 24 | $1.6B | $1.1B | ||
| Q1 24 | $1.6B | $1.1B |
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.7M | $2.6M |
| Free Cash FlowOCF − Capex | $43.5M | $-2.9M |
| FCF MarginFCF / Revenue | 22.1% | -0.8% |
| Capex IntensityCapex / Revenue | 0.1% | 1.5% |
| Cash ConversionOCF / Net Profit | — | 0.34× |
| TTM Free Cash FlowTrailing 4 quarters | $136.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $43.7M | — | ||
| Q3 25 | $60.8M | $2.6M | ||
| Q2 25 | $12.0M | — | ||
| Q1 25 | $35.5M | — | ||
| Q4 24 | $33.1M | — | ||
| Q3 24 | $53.9M | $105.2M | ||
| Q2 24 | $53.2M | — | ||
| Q1 24 | $49.1M | $17.8M |
| Q4 25 | $43.5M | — | ||
| Q3 25 | $57.0M | $-2.9M | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $26.9M | — | ||
| Q4 24 | $31.0M | — | ||
| Q3 24 | $49.8M | $104.7M | ||
| Q2 24 | $51.6M | — | ||
| Q1 24 | $46.3M | $17.6M |
| Q4 25 | 22.1% | — | ||
| Q3 25 | 31.7% | -0.8% | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 15.9% | — | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 29.6% | 20.6% | ||
| Q2 24 | 29.0% | — | ||
| Q1 24 | 27.7% | 12.2% |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 2.2% | 1.5% | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 2.4% | 0.1% | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 1.7% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | 0.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.35× | ||
| Q2 24 | 2.82× | — | ||
| Q1 24 | 5.47× | 0.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
PERI
| Advertising Solutions | $231.4M | 63% |
| Search Advertising | $137.3M | 37% |
